Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. (Q39110347)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

title

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Saray Garasa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Elísabeth Pérez Ruiz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Ignacio Melero, MD-PhD

7

object named as

Ignacio Melero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

author name string

Luna Minute

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Inmaculada Rodriguez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Susana Inogés

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Pedro Berraondo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

publication date

21 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

Immunology & Cell Biology

10 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

page(s)

347-355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

Oncology meets immunology: the cancer-immunity cycle

10 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Dinutuximab: A Review in High-Risk Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

IL-21: a pleiotropic cytokine with potential applications in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

The roles of TGFβ in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

Natural killer cell recognition of missing self

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

7 January 2021

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

7 January 2021

A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2017.6

7 January 2021

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

1 reference

12 December 2020

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

1 reference

12 December 2020

Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer

1 reference

12 December 2020

Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/ICB.2017.6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28138156%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference